drugset
drugset / Trial / NCT03050450

Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors

NCT03050450 ↗

Phase 1 Terminated 8 enrolled Johns Hopkins All Children's Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Independently, both lenalidomide and vorinostat have shown promising activity in pediatric central nervous system (CNS) tumors. These are both agents that are not typically part of first-line studies, although both agents are of serious interest and are currently in clinical trials for further investigation. This study is to evaluate the combination of lenalidomide and vorinostat in high grade or progressive central nervous system tumors in children.

Timeline

Start
2016-08-10
Primary completion
2018-12-19
Completion
2018-12-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg/m2 Oral
Subject Lenalidomide Other / unclassified 50 mg/m2 Oral
Subject Lenalidomide Other / unclassified 100 mg/m2 Oral
Subject Lenalidomide Other / unclassified 150 mg/m2 Oral
Subject Vorinostat Small molecule 180 mg/m2 Oral
Subject Vorinostat Small molecule 230 mg/m2 Oral

Indications

central nervous system neoplasm